AnaptysBio’s investigational drug rosnilimab has delivered promising Phase 2b trial results for moderate-to-severe rheumatoid arthritis.| Drug Discovery and Development
$1B women's health push and RNAi advances mark JPM 2025, with solid tumor therapies gaining momentum| Drug Discovery and Development